Efficacy and safety of novel antipsychotics: A critical review

Human Psychopharmacology

Volumn 15, Issue 7, 2000, Pages 499-512

  Balestrieri, Matteo ^a,d   Vampini, Claudio ^b   Bellantuono, Cesario ^c  

^a UNIVERSITY OF UDINE   (Italy)

^b Department of Mental Health ^*  (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Amisulpride; Antipsychotic efficacy; Olanzapine; Quetiapine; Side effects; Ziprasidone; Zotepine

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; ZIPRASIDONE; ZOTEPINE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 0033707940     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3     Document Type: Review

References (67)

1. Cost-effectiveness of clozapine
2. Antipsychotic-induced weight gain: A comprehensive research synthesis
3. New antipsychotics: A critical appraisal
4. Zotepine in the treatment of schizophrenic patients with prevailing negative symptoms. A double-blind trial vs. haloperidol
5. Critical analysis and comparison of the side-effect and safety profile of the new antipsychotics
6. Olanzapine versus placebo: Results of a double-blind fixed-dose olanzapine trial
7. Olanzapine versus placebo and haloperidol. Acute phase results of North American double-blind olanzapine trial
8. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
9. Safety of olanzapine
10. Blockade of hippocampal dopamine receptors: A tool for antipsychotics with low extrapyramidal side effects
11. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
12. Treatment of negative symptoms in schizophrenia in amisulpride
13. Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
14. Zotepine in the prevention of relapse
15. Safety of amisulpride (Solian): A review of 11 clinical studies
16. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
17. Amisulpride versus haloperidol in treatment of schizophrenic patients. Results of a double-blind study
18. ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia
19. Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
20. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes
21. Zotepine vs. haloperidol in paranoid schizophrenia: A double-blind trial
22. ICI 204,636 ('Seroquel') a putative new antipsychotic: Results from Phase III trials
23. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies
24. Weight gain associated with antipsychotic drugs
25. New antipsychotics: The present status
26. Comments on article by Tran and colleagues, Double-blind comparisons of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders
27. Preclinical pharmacology of new atypical antipsychotic in late stage development
28. A review of the safety and tolerability of sertindole
29. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder
30. Amisulpride versus flupenthixol in the treatment of schizophrenia with predominant positive symptomatology: A controlled double-blind study
31. Clozapine for the treatment-resistant schizophrenic: A double blind comparison with chlorpromazine
32. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia
33. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile and pharmacologic activity
34. Efficacy and safety of risperidone in the long-term treatment patients with schizophrenia
35. A multicentre, double-blind, controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalized patients with acute exacerbation of subchronic and chronic schizophrenia
36. Olanzapine treatment after clozapine-induced agranulocytosis
37. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
38. Newer antipsychotics
39. Multiple outcome criteria in schizophrenia: An overview of outcome with clozapine
40. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study
41. 2 Receptor occupancy of ziprasidone in healthy volunteers
42. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison to haloperidol
43. Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile
44. The efficacy and safety profile of a new antipsychotic, ziprasidone
45. Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients
46. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
47. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
48. Prospects of pharmacotherapy of schizophrenia
49. Amisulpride in the treatment of acute exacerbations of subchronic or chronic schizophrenia: A dose-range finding study
50. Efficacy and safety of ziprasidone: An update
51. Comparison of efficacy of zotepine and thiotixene in schizophrenia in a double-blind study
52. 3 receptor antagonist with both presynaptic and limbic selectivity
53. Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'
54. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
55. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo
56. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol
57. Psychopharmacology of olanzapine. A review
58. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients
59. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
60. Negative symptoms: A path analytic approach to a double-blind placebo and haloperidol controlled clinical trial with olanzapine
61. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
62. Depressive signs and symptoms in schizophrenia
63. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
64. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
65. Risperidone: Efficacy and safety
66. Clinical experience with olanzapine, a new atypical antipsychotic